Monitoring Cognition in Patients Undergoing Anti‐Amyloid Therapies with A Remote App‐Based Digital Cognitive Assessment Tool

This pilot study shows mCAPP's usability for both in-clinic and at-home use in a cohort of patients undergoing AAT. Performance across measures indicate initial reliability and validity of mCAPP. Future analyses will include the evaluation of mCAPP performance across multiple timepoints, practice effects compared to participants with unimpaired cognition, and longitudinal data analysis over the course of anti-amyloid treatment.